Eisai Enters Global Agreement with Broad Institute of US to Develop New Drugs for NTDs and Tuberculosis

Eisai announced on November 8 that it has entered a global agreement with the Broad Institute of the US (Cambridge, Massachusetts), a collaborative research facility shared by Harvard University and the Massachusetts Institute of Technology (MIT), to jointly discover and...read more